Survodutide
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
Boehringer Ingelheim · Phase 2 · Completed · Enrollment 387
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 0.6 mg BI 456906 | 36 participants | 13 participants | 22 participants | n/r | 0 |
| Placebo group | 15 participants | 4 participants | 8 participants | n/r | 0 |
| 2.4 mg BI456906 | 60 participants | 28 participants | 21 participants | n/r | 0 |
| 3.6 mg BI 456906 | 45 participants | 28 participants | 17 participants | n/r | 0 |
| 4.8 mg BI 456906 | 32 participants | 13 participants | 9 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.